| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00393-016-0258-0 |
| P698 | PubMed publication ID | 28097391 |
| P50 | author | Martin Aringer | Q42326413 |
| P2093 | author name string | R Fischer-Betz | |
| N Leuchten | |||
| P2860 | cites work | A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus | Q28254310 |
| Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial | Q28304807 | ||
| Methotrexate toxicity. Myths and facts | Q30318490 | ||
| Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry. | Q30967810 | ||
| EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics | Q33284736 | ||
| Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients | Q33357081 | ||
| The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide | Q33401164 | ||
| Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: a systematic review. | Q33415332 | ||
| Mycophenolate mofetil decreases acute rejection and may improve graft survival in renal transplant recipients when compared with azathioprine: a systematic review | Q33419795 | ||
| Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis | Q34244145 | ||
| Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis | Q34975939 | ||
| Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis | Q36302245 | ||
| Risk factors for osteoporosis and fragility fractures in patients with systemic lupus erythematosus | Q36517231 | ||
| Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care | Q37121787 | ||
| Long-term safety of methotrexate in the treatment of rheumatoid arthritis. | Q37806348 | ||
| Use of methotrexate in patients with systemic lupus erythematosus and primary Sjögren's syndrome | Q37806368 | ||
| Current state of evidence on 'off-label' therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland--a consensus report | Q37954539 | ||
| The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment | Q38063474 | ||
| Withdrawal of therapy in non-renal systemic lupus erythematosus: is this an achievable goal? | Q38152919 | ||
| Hydroxychloroquine: a multifaceted treatment in lupus | Q38214068 | ||
| A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). | Q39019163 | ||
| Off-label use of rituximab for systemic lupus erythematosus in Europe | Q39367854 | ||
| Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). | Q39907371 | ||
| Pragmatic Treatment of Patients With Systemic Lupus Erythematosus With Rituximab: Long-Term Effects on Serum Immunoglobulins | Q40610167 | ||
| Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years | Q40639756 | ||
| Use of Rituximab in Systemic Lupus Erythematosus: A Single Center Experience Over 14 Years | Q40700770 | ||
| Impact of Chronic Glucocorticoid Treatment on Cardiovascular Risk Profile in Patients with Systemic Lupus Erythematosus | Q41029663 | ||
| Malignancy in Kidney Transplantation: A 25-Year Single-center Experience in Portugal | Q41189439 | ||
| Prolonged risk of specific malignancies following cyclophosphamide therapy among patients with granulomatosis with polyangiitis. | Q41733954 | ||
| A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus | Q41942545 | ||
| Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial | Q43205821 | ||
| Sequential therapies for proliferative lupus nephritis | Q44785533 | ||
| Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus | Q45237648 | ||
| Hydroxychloroquine: the cornerstone of lupus therapy | Q46643929 | ||
| Dose-related patterns of glucocorticoid-induced side effects | Q48427299 | ||
| Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis | Q56335982 | ||
| Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy | Q72849010 | ||
| Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial | Q79839545 | ||
| Low risk of renal flares and negative outcomes in women with lupus nephritis conceiving after switching from mycophenolate mofetil to azathioprine | Q86059231 | ||
| Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus | Q87556958 | ||
| P433 | issue | 1 | |
| P921 | main subject | systemic lupus erythematosus | Q1485 |
| P1104 | number of pages | 6 | |
| P304 | page(s) | 27-32 | |
| P577 | publication date | 2017-02-01 | |
| P1433 | published in | Zeitschrift fuer Rheumatologie | Q15763293 |
| P1476 | title | [Tapering and termination of immunosuppressive therapy : Systemic lupus erythematosus] | |
| P478 | volume | 76 |
Search more.